Company intelligence / Profile preview

Dignitana

Ownership: Private
Development stage: Other

Overview

DigniCap demonstrated 66% efficacy in pivotal trials for minimizing chemotherapy-induced hair loss, leading to FDA clearance in 2015; clinical data support its safety and efficacy for patients with solid tumors, including breast, prostate, ovarian, uterine, lung and other cancers[3][6][8].

Therapeutic areas: Oncology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

OncoMedical (Switzerland, Liechtenstein distribution)

Beyond the preview

Go deeper on Dignitana.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dignitana.

Explore the full profile